Graves’ ophthalmopathy
Conditions
Interventions
Group A:Orbital Radiotherapy
Group B:Orbital Radiotherapy combined with Intravenous Glucocorticoids
Sponsors
Department of Endocrinology, Nanfang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
25 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are diagnosised as the active moderate-severe Graves’ Ophthalmopathy based on the EUGOGO-ATA diagnostic criteria; 2. age from 25-60 years old; 3. Male and female; 4. the duration of Graves’ Ophthalmopathy less than 18 months; 5. Thyroid function is under control (FT4 is normal); 6. sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Vision-threatening Graves' ophthalmopathy; 2. patients with Optic atrophy, cataracts and retinopathy; 3. CAS score70; 5. the duration of Graves’ Ophthalmopathy more than 18 months; 6. Clinical hyperthyroidism or hypothyroidism(not include normal serum free T4 levels); 7. Use of intravenous corticosteroid treatment within 12 months; 8. Use of oral corticosteroid treatment within 6 months; 9. Use of Orbital Radiotherapy treatment within 12 months; 10. Pregnancy and lactating women; 11. Abnormal liver function (Transaminase higher than 2.5 times the upper limit of normal) and abnormal renal function(blood Scr >136µmol/L); 12. Active hepatitis; 13. Severe hypertension (Grade II or more than Grade II); 14. Patients with dia 23)betic retinopathy or the use of insulin therapy or poor glycemic control (HbA1c > 8%) or acute metabolic disorders; 15. Active peptic ulcer; 16. Intraocular pressure (glaucoma or green eyelashes syndrome); 17. Active infection (especially tuberculosis); 18. Patients with a history of severe cardiovascular disease (heart failure, coronary heart disease, stroke); 19. Osteoporosis; 20. Other thyroid diseases, including: thyroid tumors (benign and malignant), Hashimoto's thyroiditis, subacute thyroiditis, primary hypothyroidism; 21. Cancer (including hematological neoplasms); 22. Moderate to severe anemia and leukopenia; 23. Cachexia, and other low resistance person; 24. Disabled use of Glucocorticoid due to other disease; 25. Reluctant to sign the informed consent or unable to complete the entire course of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms;Clinical severity assessment;Clinical activity assessment;Orbital MRI examinations;self-assessment evaluation;Safety assessment; | — |
Countries
China
Contacts
Public ContactYaoming Xue
Outcome results
None listed